# First-in-Human Study of the GDF-15 Neutralizing Antibody Visugromab (CTL-002) in Patients With Advanced Cancer (GDFATHER)

> **NCT04725474** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **CatalYm GmbH** · enrollment: 263 (actual)

## Conditions studied

- Solid Tumor, Adult

## Interventions

- **BIOLOGICAL:** visugromab (CTL-002)

## Key facts

- **NCT ID:** NCT04725474
- **Lead sponsor:** CatalYm GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-12-09
- **Primary completion:** 2028-04-30
- **Final completion:** 2030-04-30
- **Target enrollment:** 263 (ACTUAL)
- **Last updated:** 2026-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04725474

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04725474, "First-in-Human Study of the GDF-15 Neutralizing Antibody Visugromab (CTL-002) in Patients With Advanced Cancer (GDFATHER)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04725474. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*